BREAKTHROUGH CAR-T THERAPY IN REFRACTORY B-CELL LYMPHOMA: MIOT INTERNATIONAL CHENNAI, INDIA CASE STUDY

Kishore Kumar
Chezhian Subash
Srinivasan
FULL TEXT:

Abstract

CAR-T cell therapy has emerged as a novel treatment for relapsed refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), offering a significant survival benefit in patients with limited options. This case highlights the journey of a 60-year-old male with primary chemotherapy-refractory diffuse large B-cell lymphoma (DLBCL), treated with anti-CD19 CAR-T cell therapy (NEXCAR19) at MIOT International, Chennai.

Keywords:

About the Authors

Kishore Kumar
Institute of Haematology, Haemato-Oncology and Bone Marrow Transplant, MIOT INTERNATIONAL Hospital
Chezhian Subash
Institute of Haematology, Haemato-Oncology and Bone Marrow Transplant, MIOT INTERNATIONAL Hospital
Srinivasan
Institute of Haematology, Haemato-Oncology and Bone Marrow Transplant, MIOT INTERNATIONAL Hospital

How to Cite

Kishore , K., Chezhian , S., & S, K. (2025). BREAKTHROUGH CAR-T THERAPY IN REFRACTORY B-CELL LYMPHOMA: MIOT INTERNATIONAL CHENNAI, INDIA CASE STUDY. Herald of the National Children’s Medical Center, 143–144. Retrieved from https://hnchmc.uz/index.php/jour/article/view/182
Views: 22